PCSA (Processa Pharmaceuticals) PB Ratio: (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PCSA Processa Pharmaceuticals Inc PCSA
31 GF Score
Price $2.17
! 1 Warning Sign
View Full Analysis

What is Processa Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-25), Processa Pharmaceuticals's share price is $2.17. Processa Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2026 was $-0.11. Hence, Processa Pharmaceuticals's PB Ratio of today is .

The historical rank and industry rank for Processa Pharmaceuticals's PB Ratio or its related term are showing as below:

PCSA's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.955
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Processa Pharmaceuticals's average Book Value Per Share Growth Rate was -103.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -79.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -71.00% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Processa Pharmaceuticals was 180.10% per year. The lowest was -79.00% per year. And the median was -41.20% per year.

Back to Basics: PB Ratio


Processa Pharmaceuticals  (NAS:PCSA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Processa Pharmaceuticals PB Ratio Related Terms


Processa Pharmaceuticals PB Ratio Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals PB Ratio Chart

Processa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.98 2.36 1.71 1.93 1.33

Processa Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 1.74 1.33 2.66 0.00

PCSA vs BOLT, BRTX, LIMN: PB Ratio Comparison

For the Biotechnology subindustry, Processa Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Processa Pharmaceuticals PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Processa Pharmaceuticals's PB Ratio falls into.


PCSA
31GF Score
Processa Pharmaceuticals Inc PCSA
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Processa Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Processa Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2026)
=2.17/-0.113
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Processa Pharmaceuticals Business Description

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
31GF Score

Get the complete analysis for PCSA

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.17
Price